| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 35.1 | 1.6 |
| Profit before tax | -166.3 | -159.0 |
| Net income | -191.6 | -113.5 |
| EPS (diluted, $ a share) | $-0.27 | $-0.17 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +2135.6% |
|---|
10-Q filed with the SEC, NASDAQ: ROIV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Roivant Sciences Ltd.: key numbers
- Share price
- $38.61Close, Nov 16
- Market cap
- $28B
- Shares outstanding
- 724.56MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Roivant Sciences Ltd.
All →Roivant Sciences CFO Richard Pulik Sells $12.5M of Stock
Richard Pulik, CFO, sold 300,000 shares of Roivant Sciences Ltd. at $41.20 to $42.03 a share (average $41.58) in 4 transactions, worth $12.5M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 222,046 (-17.7%).
- Value
- $12.5M
- Shares
- 300,000
- Average price
- $41.58
- Role
- CFO
- Holding change
- -17.7%
- Trade date
- Nov 10, 2026 to Nov 11, 2026
Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.62M of Stock
Eric Venker, President & Immunovant CEO, sold 187,943 shares of Roivant Sciences Ltd. at $40.44 to $41.00 a share (average $40.53) in 2 transactions, worth $7.62M in total on Nov 10, 2026. Shares held after the trade: 811,211 (-3.5%).
- Value
- $7.62M
- Shares
- 187,943
- Average price
- $40.53
- Role
- President & Immunovant CEO
- Holding change
- -3.5%
- Trade date
- Nov 10, 2026
Roivant Sciences Financial Results
Roivant Sciences reported financial results for its second fiscal quarter ended September 30, 2026, highlighted by $31.0 million in net product revenue from the first five weeks of the LISRAYA launch. The company also announced positive clinical data for IMVT-1402 in rheumatoid arthritis and brepocitinib in non-infectious uveitis, ending the period with $4.2 billion in cash and marketable securities.
- Term
- Q2 2026
“This quarter has marked a major transition for Roivant. LISRAYA is now commercially available to patients and we are off to a strong start, with $31.0 million in net product revenue in the first 5 weeks of launch – reflecting strong early patient and prescriber demand.”
Matt Gline, CEO of Roivant
“Today we are thrilled to announce that IMVT-1402 succeeded in Immunovant’s study in difficult-to-treat late line rheumatoid arthritis – IMVT-1402 at the 600 mg dose met the primary endpoint in Period 2, and the broader data support its potential to maintain and deepen responses in patients who have failed multiple advanced therapies and who are in need of new options.”
Matt Gline, CEO of Roivant
Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.26M of Stock
Eric Venker, President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. at $36.31 a share, worth $7.26M in total on Nov 3, 2026. Shares held after the trade: 999,154 (-16.7%).
- Value
- $7.26M
- Shares
- 200,000
- Price
- $36.31
- Role
- President & Immunovant CEO
- Holding change
- -16.7%
- Trade date
- Nov 3, 2026
Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.32M of Stock
Eric Venker, President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. at $36.59 a share, worth $7.32M in total on Oct 28, 2026. Shares held after the trade: 1,199,154 (-14.3%).
- Value
- $7.32M
- Shares
- 200,000
- Price
- $36.59
- Role
- President & Immunovant CEO
- Holding change
- -14.3%
- Trade date
- Oct 28, 2026
Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.02M of Stock
Eric Venker, President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. at $35.09 to $35.42 a share (average $35.11) in 2 transactions, worth $7.02M in total on Oct 20, 2026. Shares held after the trade: 1,399,154 (-1.0%).
- Value
- $7.02M
- Shares
- 200,000
- Average price
- $35.11
- Role
- President & Immunovant CEO
- Holding change
- -1.0%
- Trade date
- Oct 20, 2026